Answers are grounded in this paper and cite their sources.
In a double-blind crossover trial, carbamazepine, an anticonvulsant with primary effects on subcortical limbic structures, decreased the severity of behavioral dyscontrol in 11 women with borderline personality disorder significantly more than placebo. The authors emphasize the preliminary nature of their findings and discuss alternative hypotheses regarding mechanisms by which carbamazepine might influence behavioral dyscontrol.
No takes yet. Share an insight, caveat, or question.
Gardner et al. (1986) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: